Xeris Biopharma Holdings, Inc.
XERS
$6.96
-$0.22-3.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 621.00K | -1.93M | -9.22M | -5.11M | -15.74M |
| Total Depreciation and Amortization | 3.19M | 3.16M | 3.14M | 3.13M | 3.12M |
| Total Amortization of Deferred Charges | 843.00K | 820.00K | 844.00K | 824.00K | 803.00K |
| Total Other Non-Cash Items | 7.64M | 5.01M | 4.44M | 3.61M | 2.83M |
| Change in Net Operating Assets | 6.14M | -6.88M | -9.24M | -474.00K | 674.00K |
| Cash from Operations | 18.43M | 182.00K | -10.03M | 1.98M | -8.31M |
| Capital Expenditure | -71.00K | -279.00K | -13.00K | -220.00K | -87.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 10.24M | 10.00M |
| Cash from Investing | -71.00K | -279.00K | -13.00K | 10.02M | 9.91M |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | 11.83M |
| Issuance of Common Stock | 14.33M | 1.80M | 4.86M | 564.00K | 0.00 |
| Repurchase of Common Stock | -478.00K | -860.00K | -8.00M | -166.00K | -83.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | -11.83M |
| Cash from Financing | 13.85M | 942.00K | -3.14M | 398.00K | -83.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.21M | 845.00K | -13.18M | 12.39M | 1.53M |